CTOs on the Move

ADMEDES SCHUESSLER GmbH

www.admedes.com

 
ADMEDES SCHUESSLER GmbH is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.admedes.com
  • 808 General Sterling Dr
    West Chester, PA USA 19382
  • Phone: 610.793.2746

Executives

Name Title Contact Details

Similar Companies

Ikaria

Ikaria is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Beacon Biotechnology

Beacon Biotechnology is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medicenna Therapeutics Corporation

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna`s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna`s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna`s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

Clemson University Biomedical Engineering Innovation Campus

The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.

Orna Therapeutics

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna`s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.